| pubmed-article:17941001 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17941001 | lifeskim:mentions | umls-concept:C0007082 | lld:lifeskim |
| pubmed-article:17941001 | lifeskim:mentions | umls-concept:C0034802 | lld:lifeskim |
| pubmed-article:17941001 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:17941001 | lifeskim:mentions | umls-concept:C0854983 | lld:lifeskim |
| pubmed-article:17941001 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
| pubmed-article:17941001 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:17941001 | lifeskim:mentions | umls-concept:C0430420 | lld:lifeskim |
| pubmed-article:17941001 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:17941001 | pubmed:dateCreated | 2007-12-10 | lld:pubmed |
| pubmed-article:17941001 | pubmed:abstractText | The presence of epidermal growth factor receptor (EGFR) gene mutations is a good indicator of the clinical efficacy of gefitinib in patients with nonsmall cell lung cancer. It was recently reported that the serum carcinoembryonic antigen (CEA) level could be a predictive factor for the efficacy of gefitinib treatment; therefore, it is suggested that the EGFR gene mutation is associated with the serum CEA level. The current study analyzed the association between EGFR gene mutations and clinical features, including the serum CEA level, in patients with recurrent lung adenocarcinomas. | lld:pubmed |
| pubmed-article:17941001 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17941001 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17941001 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:17941001 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17941001 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17941001 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:17941001 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:17941001 | pubmed:author | pubmed-author:MaeharaYoshih... | lld:pubmed |
| pubmed-article:17941001 | pubmed:author | pubmed-author:YanoTokujiroT | lld:pubmed |
| pubmed-article:17941001 | pubmed:author | pubmed-author:YoshinoIchiro... | lld:pubmed |
| pubmed-article:17941001 | pubmed:author | pubmed-author:OkazakiHirosh... | lld:pubmed |
| pubmed-article:17941001 | pubmed:author | pubmed-author:ShojiFumihiro... | lld:pubmed |
| pubmed-article:17941001 | pubmed:author | pubmed-author:KometaniTakur... | lld:pubmed |
| pubmed-article:17941001 | pubmed:author | pubmed-author:MiuraNaokoN | lld:pubmed |
| pubmed-article:17941001 | pubmed:author | pubmed-author:TakenakaTomoy... | lld:pubmed |
| pubmed-article:17941001 | pubmed:author | pubmed-author:KousoHidenori... | lld:pubmed |
| pubmed-article:17941001 | pubmed:author | pubmed-author:OhbaTaroT | lld:pubmed |
| pubmed-article:17941001 | pubmed:copyrightInfo | 2007 American Cancer Society | lld:pubmed |
| pubmed-article:17941001 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17941001 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:17941001 | pubmed:volume | 110 | lld:pubmed |
| pubmed-article:17941001 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17941001 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17941001 | pubmed:pagination | 2793-8 | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:meshHeading | pubmed-meshheading:17941001... | lld:pubmed |
| pubmed-article:17941001 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17941001 | pubmed:articleTitle | Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. | lld:pubmed |
| pubmed-article:17941001 | pubmed:affiliation | Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan. fshoji@surg2.med.kyushu-u.ac.jp | lld:pubmed |
| pubmed-article:17941001 | pubmed:publicationType | Journal Article | lld:pubmed |
| entrez-gene:1956 | entrezgene:pubmed | pubmed-article:17941001 | lld:entrezgene |
| entrez-gene:1048 | entrezgene:pubmed | pubmed-article:17941001 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17941001 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17941001 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17941001 | lld:entrezgene |
| lhgdn:association:3901 | lhgdn:found_in | pubmed-article:17941001 | lld:lhgdn |
| lhgdn:association:6810 | lhgdn:found_in | pubmed-article:17941001 | lld:lhgdn |
